載入...
Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors
Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...
Na minha lista:
| 發表在: | Cell Death Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832419/ https://ncbi.nlm.nih.gov/pubmed/29487283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0340-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|